Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software.
QuPath
breast cancer
scoring protocol
tumour immune infiltration
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
04
02
2020
accepted:
18
03
2020
pubmed:
14
4
2020
medline:
7
4
2021
entrez:
14
4
2020
Statut:
ppublish
Résumé
As important prognostic and predictive information can be obtained from the composition, functionality and spatial arrangement of different immune cell subtypes, this study aims at characterizing the immune infiltrate in breast tumours. Tumour-infiltrating lymphocytes (TILs) in 62 patients with luminal B-like breast cancer were characterised by immunohistochemical staining with standard markers, and were subsequently classified and quantified by the use of QuPath software. In different delineated tumour regions, the proportion and density of CD3 The QuPath scoring protocol can adequately identify positively stained immune cells in breast tumours, and allows the evaluation of differences in immune cell proportion and density within different tumour regions. The entire tumour section can be quantitatively assessed quite rapidly, which is a major advantage over manual counting.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-91Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Dushyanthen S, Beavis PA, Savas P et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015; 13; 202.
Salgado R, Denkert C, Demaria S et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 2015; 26; 259-271.
Hendry S, Salgado R, Gevaert T et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv. Anat. Pathol. 2017; 24; 311-335.
Cancer II-OBWGoB. Everything you need to know about TILs in cancer 2019. Available at: https://www.tilsinbreastcancer.org/.
Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313; 1960-1964.
Galon J, Mlecnik B, Bindea G et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J. Pathol. 2014; 232; 199-209.
Pages F, Mlecnik B, Marliot F et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018; 391; 2128-2139.
Hendry S, Salgado R, Gevaert T et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv. Anat. Pathol. 2017; 24; 235-251.
Bankhead P, Loughrey MB, Fernández JA et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 2017; 7; 16878.
Bankhead P. Creating annotations around the tumor 2018. Available at: https://petebankhead.github.io/qupath/scripts/2018/08/08/three-regions.html.
Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin. Biochem. Rev. 2008;29 (Suppl 1), S49-S52.
Galon J, Pagès F, Marincola FM et al. The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 2012; 10; 1.
Bonaventura P, Shekarian T, Alcazer V et al. Cold tumors: a therapeutic challenge for immunotherapy. Front. Immunol. 2019; 10; 168.
Loughrey MB, Bankhead P, Coleman HG et al. Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis. Histopathology 2018; 73; 327-338.
Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 2010; 28; 1684-1691.
Meng S, Li L, Zhou M, Jiang W, Niu H, Yang K. Distribution and prognostic value of tumor-infiltrating T cells in breast cancer. Mol. Med. Rep. 2018; 18; 4247-4258.
Wagner J, Rapsomaniki MA, Chevrier S et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 2019; 177; 1330-45.e18.
Konig L, Mairinger FD, Hoffmann O et al. Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer. BMC Cancer 2019; 19; 120.